TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven grade II, III, or IV astrocytoma or oligodendroglioma~  * Evidence of primary or recurrent tumor by MRI~ * Resectable disease~    * At least 20,000,000 viable cells obtained from surgical specimen for use in the immunization part of this study~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* SWOG 0 or 1~Life expectancy:~* At least 6 months~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least lower limit of normal~* No active or recent uncontrolled bleeding~Hepatic:~* Bilirubin normal~* SGOT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)~Renal:~* Creatinine normal~Other:~* Able to be weaned off steroids~* Negative stool guaiac~* No impaired immunity~* No uncontrolled diabetes~* No active uncontrolled infections~* No other serious disease~* No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix~* No psychological, familial, sociological, or geographical conditions that would preclude compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No concurrent chemotherapy except for progressive disease~Endocrine therapy:~* See Disease Characteristics~Radiotherapy:~* Radium implants allowed~Surgery:~* Not specified~Other~* At least 1 week since prior therapy and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* spine related and extremity pain lasting for 3 months or longer~* pain with Numeric Rating Scale (NRS) at 4 or higher in the past 72 hours~* good overall health condition based on the medical history and clinical laboratory tests~* participants using appropriate contraception in case of childbearing potential during the study period.~Exclusion Criteria:~* history of hypersensitive reaction to narcotic analgesics~* history of narcotic abuse~* serious psychotic disorder~* unable to use transdermal analgesics due to a dermatological condition~* history of CO2 retention (e.g., chronic obstructive pulmonary disease)~* surgery in the area with pain within 7 days prior to initiation of the clinical study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl-TTS (Type: EXPERIMENTAL): Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Wear-Time Trial for Self-Fitting Hearing Aid

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild-to-moderate bilateral sensorineural hearing loss (thresholds from 250 - 8000 Hz less than 60 decibels Hearing Level (dB HL) and from 2000 - 8000 Hz, at least one threshold greater than 20 dB HL)~* Mix of male and female subjects (aiming for a representative balance)~* Mix of prior hearing-aid use (aiming for 70-80% persons with no prior hearing aid use)~* 18-75 years old (aiming for primarily 50-70 years old, with avg. age \~65 years)~* Apple iPhone (iOS 14 compatible or greater, as required for the SELF-FIT app)~* Able to read and comprehend English~* Patient willing to provide informed consent~Exclusion Criteria:~* Hearing outside of limits noted above~* Self-reported ear-related pathology (including chronic severe dizziness or chronic severe tinnitus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Pro-Fit followed by Self Fit (Type: EXPERIMENTAL): Hearing aids fit by a professional hearing care provider using best practices followed by patient ...
- Self-Fit followed by ProFit (Type: EXPERIMENTAL): Hearing aids fit by patient followed by ...

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with de novo or relapsed AL (AML, ALL)started chemotherapy~* All newly allogeneic or autologous transplant recipients during the study period

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Acute leukemia patients (Type: None): Patients with de novo or relapsed acute myeloid and lymphoid leukemia
- Allo- or auto- transplant recipients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Kidney Disease (CKD) Stage 3, 4, or 5 (not on dialysis), Glomerular Filtration Rate (GFR) \[\<60 mL/min/1.73 m2\], or CKD Stage 2 (GFR 61-90 mL/min/1.73 mm2) with evidence of kidney damage (defined as structural or functional abnormalities of the kidneys) for greater than 3 months~* Hb \<11 g/dL measured at screening and a stable creatinine over the last 3 months~* expected to stay in a Long Term Care (LTC) facility for at least six months~* not receiving erythropoietic agents within eight weeks prior to screening.~Exclusion Criteria:~* No significant hematological disease (including, but not limited to, myelodysplastic syndrome, hematological malignancy, hemolytic syndromes, hemoglobinopathy), or with a current diagnosis of anemia due to blood loss (e.g., hemolysis or gastrointestinal bleeding) or any cause of anemia other than CKD (e.g., hypothyroidism, HIV)~* No history of deep venous thrombosis (DVT) or pulmonary embolus (PE) within 12 months prior to screening (prior superficial thrombophlebitis is not an exclusion criterion), or a history of cerebrovascular accident (CVA), transient ischemic attack (TIA), Acute Coronary Syndrome (ACS), or other arterial thrombosis within 6 months before study entry. \[ACS includes Unstable Angina, Q wave Myocardial Infarction and non-Q wave Myocardial Infarction\]~* No uncontrolled or severe cardiovascular disease including uncontrolled hypertension (systolic BP \> 170 mm/Hg, or diastolic BP \> 100 mm/Hg), or congestive heart failure (New York Heart Association (NYHA) Class IV)~* No known solid tumor malignancy, receiving chemotherapy for cancer or having major surgery within one month prior to screening or expected during study participation~* No history of receiving a transplanted organ, or scheduled to receive an organ transplant during the course of the study, with the exception of a corneal transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin Alfa (Type: EXPERIMENTAL): None
- Group 2 (Type: OTHER): Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hypertension at the range 180-120 mm of Hg for Systole \&~* 110-80 mm of Hg for Diastole~Exclusion Criteria:~* Patients who are on ACEI / ARB for Hypertension~* Diseases in which life expectancy is less than six months~* Secondary hypertension~* CHD~* Family History of Mental Illness like Anxiety or depression.~* Nasal Congestion

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 19 and 80 years~Exclusion Criteria:~* Diet containing capsaicin (Cayenne pepper, capsicum) (spicy foods), more than once a week.~* Meal containing capsaicin (spicy foods) within 5 days prior to the experiment.~* Any lesion, cracking, cold sore or abrasion on the lips~* Inability to tolerate capsaicin containing spicy foods~* Wearing lipstick or lip balm on the upper lip~* Inability to fill out an NRS pain scale~* Use of painkilling medication, within 24 hours of the study.~* Allergy to any of the ingredients of the creams, or to mannitol~* History of contact or allergic dermatitis~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Mannitol in vehicle cream (Type: ACTIVE_COMPARATOR): Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have been previously treated CLL/SLL~* Must have CD20 expression~* ECOG PS =\<3~* No prior Campath-1H~* No active infection requiring antibiotics~* No concurrent immunosuppressive therapy~* No prior history demyelinating neurologic disease~* No active viral hepatitis~Exclusion Criteria:~* No pregnant or breastfeeding women~* ECOG PS =4~* Life expectancy of \>12 weeks~* Patients with bilirubin or creatinine\>3.0 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Adult Lower Limb Spasticity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 to 80 years of age~* Post stroke or brain injury~* Intensity of muscle tone greater than or equal to 2, as measured on the Modified Ashworth Scale~* Ambulatory patients~Exclusion Criteria:~* Fixed contractures~* Physiotherapy initiated less than 4 weeks before entry~* Previous surgery or previous treatment with phenol and/or alcohol in lower limb~* Neurological/neuromuscular disorders which may interfere with protocol evaluations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dysport® 1000 U, IM (Type: EXPERIMENTAL): 1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
- Dysport® 1500 U, IM (Type: EXPERIMENTAL): 1500 U, I.M., on day 1 (single treatment cycle)
- Placebo (Type: PLACEBO_COMPARATOR): I.M., on day 1 (single treatment cycle)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients with confirmed MCI diagnosis~* Age 55-85~* Right handed (tested using the Edinburgh handedness inventory)~* Total PHQ-8 of ≤ 16 which signifies no severe depression~* All participants and/or caregivers must be able to provide informed consent~Exclusion Criteria:~* Neurodegenerative disease (e.g. Parkinson's, Huntington's, Multiple Sclerosis) other than MCI~* Previous brain lesion~* Intracranial abnormality such as prior stroke~* History of seizure disorder or epilepsy~* A true positive response, after patient clarification, to any question on the modified TMS/tDCS Adult Safety Screen questionnaire that would impact patient safety~* Any history of brain stimulation treatment (e.g., electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), vagal nerve therapy (VNS), deep brain stimulation (DBS))~* Use of any investigational drug within 4 weeks~* Cardiac pacemakers, implanted medication pumps, intracardiac lines; acute or unstable cardiac disease; intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head (exception: mouth/dental work) that cannot be safely removed~* Known or suspected pregnancy (extremely unlikely as the age range for this study is 55-85 years)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Active tDCS (Type: ACTIVE_COMPARATOR): Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
- Sham tDCS (Type: SHAM_COMPARATOR): Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of knee or hip osteoarthritis with history of pain at the reference joint for at least 3 months or clinical diagnosis of low back pain of benign origin for at least 3 months~* Must be dissatisfied with their current analgesic therapy (e.g. Non-steroidal anti-inflammatory drugs NSAIDS, COX-2 inhibitors, opioids, paracetamol/acetaminophen~* Have a pain intensity \>4 on Numerical Rating Scale~Exclusion Criteria:~* Life-long history of seizure disorder or epilepsy~* Any of the following within one year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, and brain neoplasm~* Severe traumatic brain injury within 15 years (consisting of more than one of the following: brain contusion (injuries resulting in hemorrhage), intracranial hematoma, unconsciousness or post traumatic amnesia lasting for more than 24 hours) or residual sequelae suggesting transient changes in consciousness~* History of malignancy within past 2 years, with exception of a successfully treated basal cell carcinoma~* Presence of significant pain associated with conditions other than osteoarthritis or low back pain that could confound the assessment or self-evaluation of pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapentadol (CG5503) (Type: EXPERIMENTAL): Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
- Oxycodone (Type: ACTIVE_COMPARATOR): Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Proactive Tobacco Treatment for Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current smoker, identified by tobacco use clinical reminder.~Exclusion Criteria:~* ICD-9 diagnosis of dementia (290.xx or 331.xx).~* Greater than 10 VA mental health clinic visits in past 12 months.~* Missing phone number or mailing address.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Group who can elect to receive reactive (usual) care for smoking cessation.
- Proactive Care (Type: EXPERIMENTAL): Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* primary single or bilateral lung allograft~* original disease cystic fibrosis, COPD, emphysema, idiopathic pulmonary fibrosis or A1AD~Exclusion Criteria:~* lung allograft retransplantation~* multiple organ transplantation~* severe gastrointestinal disorder~* malignancies or history of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil; Cystic Fibrosis (Type: EXPERIMENTAL): Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
- Mycophenolate Mofetil; Other (Type: EXPERIMENTAL): Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete